Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis

Semaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with demonstrated cardiovascular benefits; semaglutide may also have kidney-protective effects. This post hoc analysis investigated the associ...

Source: Cardiovascular Diabetology - August 24, 2023 Category: Cardiology Authors: Peter Rossing, Stephen C. Bain, Heidrun Bosch-Traberg, Ekaterina Sokareva, Hiddo J. L. Heerspink, S øren Rasmussen and Linda G. Mellbin Tags: Research Source Type: research